These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 21368892)
1. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Liu Y; Lang F; Xie X; Prabhu S; Xu J; Sampath D; Aldape K; Fuller G; Puduvalli VK Cell Death Dis; 2011 Feb; 2(2):e121. PubMed ID: 21368892 [TBL] [Abstract][Full Text] [Related]
2. Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. Naumann U; Waltereit R; Schulz JB; Weller M J Neurooncol; 2003 Jan; 61(1):7-15. PubMed ID: 12587790 [TBL] [Abstract][Full Text] [Related]
3. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708 [TBL] [Abstract][Full Text] [Related]
4. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138 [TBL] [Abstract][Full Text] [Related]
5. Experiment research on inhibition of glioma with sTRAIL in vitro. Dou Y; Wang Y; Xu J; Li Z; Sun P; Meng Q Artif Cells Nanomed Biotechnol; 2014 Jun; 42(3):186-91. PubMed ID: 24156316 [TBL] [Abstract][Full Text] [Related]
6. In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas. Uzzaman M; Keller G; Germano IM Neuro Oncol; 2009 Apr; 11(2):102-8. PubMed ID: 18676359 [TBL] [Abstract][Full Text] [Related]
7. Cancer gene therapy using a novel secretable trimeric TRAIL. Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915 [TBL] [Abstract][Full Text] [Related]
9. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667 [TBL] [Abstract][Full Text] [Related]
10. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Bremer E; van Dam GM; de Bruyn M; van Riezen M; Dijkstra M; Kamps G; Helfrich W; Haisma H Mol Ther; 2008 Dec; 16(12):1919-26. PubMed ID: 18813279 [TBL] [Abstract][Full Text] [Related]
11. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508 [TBL] [Abstract][Full Text] [Related]
12. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547 [TBL] [Abstract][Full Text] [Related]
13. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma. Park SA; Han HR; Ahn S; Ryu CH; Jeun SS Oncol Rep; 2021 Mar; 45(3):869-878. PubMed ID: 33469674 [TBL] [Abstract][Full Text] [Related]
14. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303 [TBL] [Abstract][Full Text] [Related]
15. Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. Yulyana Y; Endaya BB; Ng WH; Guo CM; Hui KM; Lam PY; Ho IA Stem Cells Dev; 2013 Jul; 22(13):1870-82. PubMed ID: 23428290 [TBL] [Abstract][Full Text] [Related]
16. MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth. Bo Y; Guo G; Yao W J Neurooncol; 2013 Mar; 112(1):27-37. PubMed ID: 23338605 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells. Kim KU; Seo SY; Heo KY; Yoo YH; Kim HJ; Lee HS; Choi SS; Hwang TH; Lee HJ J Korean Med Sci; 2005 Dec; 20(6):1046-52. PubMed ID: 16361820 [TBL] [Abstract][Full Text] [Related]
18. Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy. Kim CY; Park SH; Jeong M; Kwon OS; Doh H; Kang SH; Robbins PD; Kim BM; Seol DW; Kim BG Exp Mol Med; 2011 Oct; 43(10):580-6. PubMed ID: 21822049 [TBL] [Abstract][Full Text] [Related]
19. KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway. Siegelin MD; Siegelin Y; Habel A; Rami A; Gaiser T Neurobiol Dis; 2009 May; 34(2):259-66. PubMed ID: 19385057 [TBL] [Abstract][Full Text] [Related]